Introduction

Abstract

This is the fourth issue of our Monograph on Endocrine Therapy of Breast Cancer. As in the past, this volume is the result of highly interesting discussions among the members of the Task Force and several guests, all of them outstanding researchers in their respective fields. To discuss controversial issues pertaining to data deriving from one’s own work is an extremely pleasant exercise, and at the same time generates both sound criticism and new hypotheses; the latter is essential for the continuation of productive research. The 1990 edition contains the following four items of notable interest: 1) new data concerning the function of oestrogen and progesterone in promoting receptormediated growth; 2) a definition of prognostic factors in breast cancer, particularly in node-negative disease; 3) new data about “old” endocrine therapies; and 4) a discussion of adjuvant therapies and the measure of their benefit, with special emphasis on quality-of-life considerations.